Medicare AdvantagePrior AuthHigh impact
Atezolizumab products (Tecentriq, Tecentriq Hybreza) (Revised)
Humana·FL, KY, SC · Oncology·Medicaid
We identified it
Jul 21, 2026
Summary
This is a revised Prior Authorization policy for Atezolizumab products (Tecentriq, Tecentriq Hybreza) affecting Medicare and Medicaid members in Florida, Kentucky, and South Carolina. The policy update requires immediate review to identify specific authorization requirements and any changes from the previous version.
Action Required
Immediately: Billing team must access the full policy document at https://dctm.humana.com/Mentor/Web/v.aspx?objectID=090009298a584848 to obtain specific HCPCS codes, prior authorization requirements, and clinical criteria for Atezolizumab products. Update billing system rules and provider workflows to enforce any new or revised prior authorization requirements before submitting claims for these drugs in FL, KY, and SC. Compare this revised policy against any previous version to identify what changed. Flag all Tecentriq and Tecentriq Hybreza claims for prior authorization review until staff confirms implementation. Failure to obtain prior authorization will result in claim denials and revenue impact.